Table 1:
Clinicopathologic characteristics of endometrial cancers of copy number-high (serous-like) molecular subtype by CD8+ infiltration.
| Total Cohort n (%) |
ssGSEA | CIBERSORT | |||||
|---|---|---|---|---|---|---|---|
| CD8+ low | CD8+ high |
p- value |
CD8+ low | CD8+ high |
p- value |
||
| Age (years) | |||||||
| Median (Mean) | 68 (69.05) | 67 (68.87) | 69 (69.23) | 0.584 | 71 (71.73) | 66 (66.37) | 0.015 |
| Range | 44-90 | 58-90 | 44-87 | 58-87 | 44-90 | ||
| Stage | |||||||
| I/II | 33 (55%) | 17 (56.7%) | 16 (53.3%) | 1 | 14 (46.7%) | 19 (63.3%) | 0.503 |
| III | 19 (31.7%) | 9 (30%) | 10 (33.3%) | 11 (36.7%) | 8 (26.7%) | ||
| IV | 8 (13.3%) | 4 (13.3%) | 4(13.3%) | 5 (16.7%) | 3 (10%) | ||
| Histology | |||||||
| Endometrioid | 16 (26.7%) | 6 (20%) | 10 (33.3%) | 0.382 | 3 (10%) | 13 (43.3%) | 0.007 |
| Serous/Mixed | 44 (73.3%) | 24 (80%) | 20 (66.7%) | 27 (90%) | 17 (56.7%) | ||
| Tumor grade (endometrioid) | |||||||
| G1 | 1 (1.7%) | 0 (0%) | 1 (3.3%) | ** | 0 (0%) | 1 (3.3%) | ** |
| G2 | 6 (10%) | 2 (6.7%) | 4 (13.3%) | 0 (0%) | 6 (20%) | ||
| G3 and serous/ mixed | 53 (88.3%) | 28(93.3%) | 25 (83.3%) | 30 (100%) | 23 (76.7%) | ||
| BMI kg/m2 (categorical; missing, n=3) | |||||||
| Normal (BMI<25) | 16 (28.1%) | 7 (24.1%) | 9 (32.1%) | 0.724 | 9 (31%) | 7 (25%) | 0.827 |
| Overweight (BMI:25-30) | 11 (19.3%) | 5 (17.2%) | 6 (21.4%) | 6 (20.7%) | 5 (17.9%) | ||
| Obese (BMI≥30) | 30 (52.6%) | 17 (58.6%) | 13 (46.4%) | 14 (48.3%) | 16 (57.1%) | ||
Clinicopathologic characteristics of copy number-high (serous-like) endometrial cancers by CD8+ infiltration high vs low as defined by ssGSEA and CIBERSORT using median for cutoff. All p-values reported here are unadjusted, using Fisher’s exact test for categorical variables and Wilcoxon-rank sum test for continuous variables.
**
p-value not provided if certain level has counts <5. BMI, body mass index.